Table 4.
A. Mortality status through 2011 | ||||||
---|---|---|---|---|---|---|
HR (95% CI) |
||||||
Body Composition |
Model 1 | Model 2 | Model 3 | Model 4 | ||
Entire cohort (n=11,616) | ||||||
Non-sarcopenic non-obese |
Reference | Reference | Reference | Reference | ||
Sarcopenic | 2.72 (2.25 to 3.29) | 1.62 (1.33 to 1.99) | 1.35 (1.10 to 1.67) | 1.32 (1.06 to 1.66) | ||
Obese | 2.09 (1.74 to 2.50) | 1.27 (1.05 to 1.52) | 1.09 (0.90 to 1.32) | 0.98 (0.81 to 1.18) | ||
Sarcopenic- obese |
6.99 (5.65 to 8.65) | 1.69 (1.38 to 2.06) | 1.35 (1.09 to 1.66) | 1.28 (1.04 to 1.57) | ||
Participants with eGFR ≥60 mL/min/1.73m2 (n=10,515) | ||||||
Non-sarcopenic non-obese |
Reference | Reference | Reference | Reference | ||
Sarcopenic | 2.80 (2.14 to 3.66) | 1.79 (1.37 to 2.35) | 1.44 (1.07 to 1.93) | 1.45 (1.07 to 1.97) | ||
Obese | 2.24 (1.78 to 2.81) | 1.41 (1.12 to 1.77) | 1.21 (0.96 to 1.54) | 1.09 (0.87 to 1.37) | ||
Sarcopenic- obese |
7.45 (5.65 to 9.82) | 2.09 (1.61 to 2.70) | 1.64 (1.26 to 2.13) | 1.57 (1.19 to 2.05) | ||
Participants with eGFR <60 mL/min/1.7 3m2 (n=1,101) | ||||||
Non-sarcopenic non-obese |
Reference | Reference | Reference | Reference | ||
Sarcopenic | 1.79 (1.32 to 2.44) | 1.46 (1.06 to 2.02) | 1.24 (0.89 to 1.71) | 1.14 (0.80 to 1.64) | ||
Obese | 0.93 (0.72 to 1.19) | 1.00 (0.77 to 1.30) | 0.87 (0.67 to 1.12) | 0.77 (0.59 to 1.01) | ||
Sarcopenic- obese |
1.83 (1.34 to 2.48) | 1.19 (0.88 to 1.62) | 1.05 (0.75 to 1.46) | 0.97 (0.70 to 1.35) | ||
B. Mortality status through 2006 | ||||||
HR (95% CI) |
||||||
Body Composition |
Model 1 | Model 2 | Model 3 | Model 4 | ||
Entire cohort (n=11,616) | ||||||
Non-sarcopenic non-obese |
Reference | Reference | Reference | Reference | ||
Sarcopenic | 2.99 (2.34 to 3.83) | 1.68 (1.29 to 2.19) | 1.39 (1.03 to 1.87) | 1.34 (1.00 to 1.83) | ||
Obese | 1.93 (1.51 to 2.47) | 1.18 (0.92 to 1.50) | 1.00 (0.77 to 1.28) | 0.86 (0.67 to 1.12) | ||
Sarcopenic- obese |
7.14 (5.43 to 9.40) | 1.65 (1.18 to 2.30) | 1.23 (0.83 to 1.84) | 1.17 (0.81 to 1.70) | ||
Participants with eGFR ≥60 mL/min/1.73m2 (n=10,515) | ||||||
Non-sarcopenic non-obese |
Reference | Reference | Reference | Reference | ||
Sarcopenic | 3.13 (2.20 to 4.48) | 1.95 (1.38 to 2.75) | 1.52 (1.02 to 2.26) | 1.51 (1.00 to 2.30) | ||
Obese | 2.11 (1.53 to 2.90) | 1.34 (0.97 to 1.85) | 1.15 (0.83 to 1.60) | 1.00 (0.71 to 1.40) | ||
Sarcopenic- obese |
8.26 (5.51 to 12.38) | 2.30 (1.42 to 3.72) | 1.75 (1.07 to 2.87) | 1.63 (1.02 to 2.61) | ||
Participants with eGFR <60 mL/min/1.73m2 (n=1,101) | ||||||
Non-obese non- sarcopenic |
Reference | Reference | Reference | Reference | ||
Sarcopenic | 1.79 (1.17 to 2.74) | 1.38 (0.87 to 2.18) | 1.24 (0.80 to 1.90) | 1.16 (0.74 to 1.81) | ||
Obese | 0.87 (0.62 to 1.24) | 0.94 (0.68 to 1.29) | 0.77 (0.55 to 1.07) | 0.67 (0.47 to 0.95) | ||
Sarcopenic- obese |
1.61 (1.03 to 2.50) | 0.95 (0.57 to 1.58) | 0.77 (0.48 to 1.23) | 0.73 (0.46 to 1.17) |
P-value for interaction by CKD status: A. Mortality through 2011: p=0.01; B. Mortality status through 2006: p=0.01
Abbreviations: HR, Hazard Ratio; CI, Confidence Interval; eGFR, estimated glomerular filtration rate; CKD, Chronic Kidney Disease.
Bold values indicate p<0.05.
Model 1: unadjusted
Model 2: adjusted for age, sex, race/ethnicity
Model 3: adjusted for age, sex, race/ethnicity, education level, activity level, smoking status, diagnosis of diabetes mellitus, hypertension, cardiovascular disease, history of cancer (other than non-melanoma skin cancer), eGFR categories and log-transformed urine albumin-creatinine ratio
Model 4: adjusted for age, sex, race/ethnicity, education level, activity level, smoking status, diagnosis of diabetes mellitus, hypertension, cardiovascular disease, history of cancer (other than non-melanoma skin cancer), eGFR categories, log-transformed urine albumin-creatinine ratio, serum albumin, log-transformed c-reactive protein